Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) stock has reached a 52-week low, touching down at $2.21, representing a stark 90% decline from its 52-week high of $23.80. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 7.03, though its market capitalization has contracted to just $3.75 million. This low point reflects a significant downturn from previous valuations, with the stock experiencing a substantial decline of 41% over the past year. While InvestingPro analysis suggests the stock is currently undervalued, investors are closely monitoring Galmed’s strategic moves and potential catalysts that may influence recovery. The company maintains a solid balance sheet with more cash than debt, though profitability remains a key concern according to InvestingPro metrics (6 additional InvestingPro Tips available).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.